ID   PEO6
AC   CVCL_2691
SY   PE06; PEO-6
DR   BTO; BTO_0005798
DR   EFO; EFO_0005449
DR   cancercelllines; CVCL_2691
DR   CancerTools; 151674
DR   Cell_Model_Passport; SIDM00470
DR   ECACC; 10032310
DR   GEO; GSM459855
DR   GEO; GSM659400
DR   GEO; GSM1340591
DR   GEO; GSM1341133
DR   GEO; GSM2475003
DR   Progenetix; CVCL_2691
DR   Wikidata; Q54947169
DR   Ximbio; 151674
RX   PubMed=3167863;
RX   PubMed=19654294;
RX   PubMed=20581869;
RX   PubMed=22183581;
RX   PubMed=22710073;
RX   PubMed=23415752;
RX   PubMed=28273451;
RX   PubMed=30485824;
CC   Population: Caucasian.
CC   Doubling time: 77 hours (PubMed=3167863).
CC   Sequence variation: Mutation; HGNC; HGNC:1101; BRCA2; Simple; p.Tyr1655Tyr (c.4965C>T) (5193C>T); ClinVar=VCV001657967; Zygosity=Hemizygous; Note=De novo mutation that cancels the c.4965C>G (5193C>G) mutation in the patient (PubMed=19654294).
CC   Sequence variation: Mutation; HGNC; HGNC:11998; TP53; Simple; p.Gly244Asp (c.731G>A); ClinVar=VCV000372785; Zygosity=Unspecified (PubMed=28273451).
CC   Omics: Genomics; Whole genome sequencing.
CC   Omics: Transcriptomics; Microarray.
CC   Omics: Transcriptomics; RNAseq.
CC   Omics: Variations; SNP array analysis.
CC   Discontinued: ECACC; 10032310; true.
CC   Derived from site: Metastatic; Ascites; UBERON=UBERON_0007795.
ST   Source(s): ECACC=10032310; PubMed=22183581; PubMed=22710073; PubMed=30485824
ST   Amelogenin: X
ST   CSF1PO: 10,12
ST   D13S317: 10
ST   D16S539: 9
ST   D18S51: 16
ST   D19S433: 13,15
ST   D21S11: 30 (PubMed=22710073)
ST   D21S11: 30,32.2 (PubMed=22183581; PubMed=30485824)
ST   D2S1338: 20,21
ST   D3S1358: 16
ST   D5S818: 11,12
ST   D7S820: 10
ST   D8S1179: 13,14
ST   FGA: 20
ST   TH01: 9.3
ST   TPOX: 9,11
ST   vWA: 15,16
DI   NCIt; C36101; BRCA2 syndrome
DI   NCIt; C5228; Ovarian cystadenocarcinoma
DI   ORDO; Orphanet_145; Hereditary breast and ovarian cancer syndrome
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
OI   CVCL_2686 ! PEO1
OI   CVCL_2690 ! PEO4
SX   Female
AG   Age unspecified
CA   Cancer cell line
DT   Created: 04-04-12; Last updated: 10-04-25; Version: 29
//
RX   PubMed=30485824; DOI=10.1016/j.celrep.2018.10.096; PMCID=PMC6481945;
RA   Papp, Eniko
RA   Hallberg, Dorothy
RA   Konecny, Gottfried E.
RA   Bruhm, Daniel C.
RA   Adleff, Vilmos
RA   Noe, Michael
RA   Kagiampakis, Ioannis
RA   Palsgrove, Doreen
RA   Conklin, Dylan
RA   Kinose, Yasuto
RA   White, James R.
RA   Press, Michael Frederick
RA   Drapkin, Ronny I.
RA   Easwaran, Hariharan
RA   Baylin, Stephen Bruce
RA   Slamon, Dennis Joseph
RA   Velculescu, Victor E.
RA   Scharpf, Robert B.
RT   "Integrated genomic, epigenomic, and expression analyses of ovarian
RT   cancer cell lines.";
RL   Cell Rep. 25:2617-2633(2018).
//
RX   PubMed=22710073; DOI=10.1016/j.ygyno.2012.06.017; PMCID=PMC3432677;
RA   Korch, Christopher T.
RA   Spillman, Monique Ann
RA   Jackson, Twila A.
RA   Jacobsen, Britta M.
RA   Murphy, Susan K.
RA   Lessey, Bruce Arthur
RA   Jordan, Virgil Craig
RA   Bradford, Andrew Peter
RT   "DNA profiling analysis of endometrial and ovarian cell lines reveals
RT   misidentification, redundancy and contamination.";
RL   Gynecol. Oncol. 127:241-248(2012).
//
RX   PubMed=3167863;
RA   Langdon, Simon P.
RA   Lawrie, Sandra S.
RA   Hay, Frances G.
RA   Hawkes, Mary M.
RA   McDonald, Amanda
RA   Hayward, Ian P.
RA   Schol, Dick J.
RA   Hilgers, Jo
RA   Leonard, Robert C.F.
RA   Smyth, John Fletcher
RT   "Characterization and properties of nine human ovarian adenocarcinoma
RT   cell lines.";
RL   Cancer Res. 48:6166-6172(1988).
//
RX   PubMed=20581869; DOI=10.1038/onc.2010.245; PMCID=PMC2933510;
RA   Cooke, Susanna L.
RA   Ng, Charlotte Kiu Yan
RA   Melnyk, Nataliya
RA   Garcia, Maria J.
RA   Hardcastle, Thomas James
RA   Temple, Jillian
RA   Langdon, Simon P.
RA   Huntsman, David G.
RA   Brenton, James D.
RT   "Genomic analysis of genetic heterogeneity and evolution in high-grade
RT   serous ovarian carcinoma.";
RL   Oncogene 29:4905-4913(2010).
//
RX   PubMed=22183581; DOI=10.1002/path.3980;
RA   Ng, Charlotte Kiu Yan
RA   Cooke, Susanna L.
RA   Howe, Kevin L.
RA   Newman, Scott
RA   Xian, Jian
RA   Temple, Jillian
RA   Batty, Elizabeth M.
RA   Pole, Jessica C.M.
RA   Langdon, Simon P.
RA   Edwards, Paul A.W.
RA   Brenton, James D.
RT   "The role of tandem duplicator phenotype in tumour evolution in
RT   high-grade serous ovarian cancer.";
RL   J. Pathol. 226:703-712(2012).
//
RX   PubMed=23415752; DOI=10.1016/j.molonc.2012.12.007; PMCID=PMC4106023;
RA   Stordal, Britta
RA   Timms, Kirsten
RA   Farrelly, Angela
RA   Gallagher, Danielle
RA   Busschots, Steven
RA   Renaud, Mickael
RA   Thery, Julien
RA   Williams, Deborah
RA   Potter, Jennifer
RA   Tran, Thanh
RA   Korpanty, Greg
RA   Cremona, Mattia
RA   Carey, Mark S.
RA   Li, Jie
RA   Li, Yang
RA   Aslan, Ozlem
RA   O'Leary, John J.
RA   Mills, Gordon B.
RA   Hennessy, Bryan T.
RT   "BRCA1/2 mutation analysis in 41 ovarian cell lines reveals only one
RT   functionally deleterious BRCA1 mutation.";
RL   Mol. Oncol. 7:567-579(2013).
//
RX   PubMed=28273451; DOI=10.1016/j.celrep.2017.02.028;
RA   Medrano, Mauricio
RA   Communal, Laudine
RA   Brown, Kevin R.
RA   Iwanicki, Marcin
RA   Normand, Josee
RA   Paterson, Joshua
RA   Sircoulomb, Fabrice
RA   Krzyzanowski, Paul M.
RA   Novak, Marian
RA   Doodnauth, Sasha A.
RA   Suarez Saiz, Fernando Jose
RA   Cullis, Jane
RA   Al-awar, Rima
RA   Neel, Benjamin G.
RA   McPherson, John
RA   Drapkin, Ronny I.
RA   Ailles, Laurie
RA   Mes-Masson, Anne-Marie
RA   Rottapel, Robert
RT   "Interrogation of functional cell-surface markers identifies CD151
RT   dependency in high-grade serous ovarian cancer.";
RL   Cell Rep. 18:2343-2358(2017).
//
RX   PubMed=19654294; DOI=10.1158/0008-5472.CAN-09-1178; PMCID=PMC2754824;
RA   Sakai, Wataru
RA   Swisher, Elizabeth M.
RA   Jacquemont, Celine
RA   Chandramohan, Kurapaty Venkatapoorna
RA   Couch, Fergus J.
RA   Langdon, Simon P.
RA   Wurz, Kaitlyn
RA   Higgins, Jake
RA   Villegas, Emily
RA   Taniguchi, Toshiyasu
RT   "Functional restoration of BRCA2 protein by secondary BRCA2 mutations
RT   in BRCA2-mutated ovarian carcinoma.";
RL   Cancer Res. 69:6381-6386(2009).
//